Phase II subcutaneous Ethyol data

Medimmune (MEDI) said results of a Phase II study of its Ethyol

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE